Trial Profile
Switching from injectables, fingolimod and natalizumab to oral agents, Teriflunomide and Dimethyl-fumarate in patients with relapsing-remitting multiple-sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2016
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary) ; Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 13 Sep 2016 New trial record